Swiss pharmaceutical giant Novartis announced Sunday it had agreed to buy Avidity Biosciences, with the San Diego-based biopharmaceutical company being valued at $12 billion. Novartis, based in Basel in northern Switzerland, announced in April that it planned to invest $23 billion in the United States over five years. rjm/jj
Related Articles
Don't miss out on breaking stories and in-depth articles.